Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
Last trade$0.323
Day change-$0.0188 (-5.50%)
Day range$0.306 – $0.37
Volume161,409
Market cap$7M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$6.8M
Price / earnings
—
Price / book
-3.71×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.15×
Profitability
Earnings per share
-$1.99
Return on assets
-454.1%
Return on equity
2,173.99%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-0×
Current ratio
0.34×
Quick ratio
0.34×
Cash ratio
0.19×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$16M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for TPST, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$2.62M
$3.43M
$5.43M
$3.54M
$3.03M
$4.1M
$3.31M
$3.18M
Research and development
$207K
$1.82M
$22.29M
$539K
$570K
$3.87M
$7.63M
$10.74M
Total operating expenses
$2.82M
$5.25M
$27.72M
$4.08M
$3.6M
$7.97M
$10.94M
$13.92M
Operating income
-$2.82M
-$5.25M
-$27.72M
-$4.08M
-$3.6M
-$7.97M
-$10.94M
-$13.92M
Interest expense
$0
$0
$0
$0
$0
-$46K
-$161K
-$247K
Income before taxes
-$2.82M
-$5.24M
-$27.7M
-$4.02M
-$3.6M
-$7.87M
-$10.86M
-$13.81M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$2.82M
-$5.24M
-$27.7M
-$4.02M
-$3.6M
-$7.87M
-$10.86M
-$13.81M
Net income attributable to common shareholders
-$2.82M
-$5.24M
-$27.7M
-$4.02M
-$3.6M
-$7.87M
-$10.86M
-$13.81M
EBITDA
-$2.77M
-$5.19M
-$27.66M
-$4.01M
-$3.53M
-$7.9M
-$10.87M
-$13.87M
Basic earnings per share
-$0.21
-$0.34
-$2.53
-$0.82
-$0.79
-$2.07
-$3.16
-$4.38
Diluted earnings per share
-$0.21
-$0.34
-$2.53
-$0.82
-$0.79
-$2.07
-$3.16
-$4.38
Recent news
Company coverage with links to the original publishers.
Tempest Therapeutics (TPST) announced it has exercised an option to obtain exclusive global rights (excluding China) to Senlang's CD7-targeted lentiviral vector platform and in vivo CAR-T candidates. The company's lead candidate TPST-4903, a BCMA/GPRC5D dual-targeting in vivo CAR-T, is in Phase 1 trials for relapsed/refractory multiple myeloma with encouraging preliminary results expected to be presented at an upcoming conference. Tempest also secured $50 million in equity line of credit access and $2.5 million in private placement funding, while strengthening its board with two new independent directors.
Tempest Therapeutics will present updated clinical data from its REDEEM-1 Phase 1/2a trial of TPST-2003, a dual-targeting CD19/BCMA CAR-T therapy for relapsed/refractory multiple myeloma, at the International Society for Cell & Gene Therapy Scientific Annual Meeting in Dublin (May 6-9, 2026). Earlier interim data showed a 100% complete response rate among six evaluable patients with a favorable safety profile.
Tempest Therapeutics selected Cincinnati Children's Applied Gene and Cell Therapy Center as its manufacturing partner for technology transfer of TPST-2003, a dual-targeting CD19/BCMA CAR-T therapy for relapsed/refractory multiple myeloma. The partnership supports preparation for a planned U.S. registrational study with IND filing targeted for Q4 2026. Recent interim data from the REDEEM-1 trial showed 100% complete response rate in all six efficacy evaluable patients and 100% overall response rate among 25 evaluable patients with measurable disease.
Tempest Therapeutics has agreed to acquire dual-CAR T programs from Factor Bioscience in an all-stock transaction, which is expected to extend the company's operational runway to mid-2027 and diversify its clinical-stage pipeline.
Tempest Therapeutics plans to acquire dual-CAR T programs from Factor Bioscience in an all-stock transaction, expanding its clinical-stage pipeline and extending its operational runway to mid-2027. The acquisition includes a clinical-stage CD19/BCMA dual-CAR T program and is expected to close in early 2026.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.